Tumour-Infiltrating Lymphocyte Therapy Market Size to be Worth USD 2.1 Billion by 2034, at 40 percent CAGR Prophecy Market Insights
SNDX Stock | USD 12.85 0.39 2.95% |
Slightly above 56% of Syndax Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Syndax Pharmaceuticals suggests that many traders are alarmed. Syndax Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Syndax Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Syndax |
Tumour-Infiltrating Lymphocyte Therapy Market from 2024-2034 with covered segments By Therapy Type , By Indication , By Source of TILs , and By Regional Forecast, , which provides the perfect mix of market strategies, and industrial expertise with new cutting-edge technology to give the best experience.Covina, Aug. 23, 2024 -- According
Read at finance.yahoo.com
Syndax Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Syndax Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Syndax Pharmaceuticals Fundamental Analysis
We analyze Syndax Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syndax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syndax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Syndax Pharmaceuticals is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Syndax Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Syndax Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Syndax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syndax Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Syndax Pharmaceuticals Related Equities
MRSN | Mersana Therapeutics | 2.96 | ||||
INZY | Inozyme Pharma | 1.81 | ||||
MLYS | Mineralys Therapeutics, | 1.63 | ||||
CYTK | Cytokinetics | 0.82 | ||||
RVMD | Revolution Medicines | 0.74 | ||||
PCVX | Vaxcyte | 0.54 | ||||
REPL | Replimune | 0.51 | ||||
EWTX | Edgewise Therapeutics | 0.53 | ||||
MRUS | Merus BV | 0.82 | ||||
AVTE | Aerovate Therapeutics | 1.17 | ||||
KROS | Keros Therapeutics | 1.23 | ||||
STRO | Sutro Biopharma | 1.62 | ||||
VRDN | Viridian Therapeutics | 2.85 | ||||
LRMR | Larimar Therapeutics | 4.33 | ||||
KALV | Kalvista Pharmaceuticals | 4.37 | ||||
PLRX | Pliant Therapeutics | 5.00 | ||||
DYN | Dyne Therapeutics | 6.12 | ||||
CGEM | Cullinan Oncology | 6.27 | ||||
COGT | Cogent Biosciences | 6.72 |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.